CoChat

Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study

Open access
Napoli, Raffaele, Berra, Cesare, Catarig, Andrei‐Mircea, Di Loreto, Chiara, Donatiello, Emily, Berentzen, Tina Landsvig, Pitocco, Dario, Giorgino, Francesco · 2023 · Diabetes, Obesity and Metabolism
Cited by 32

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Aims: SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study, investigated once‐weekly semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and Methods: Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled. The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Other endpoints included changes in body weight, waist circumference and patient‐reported outcomes, and the proportion of patients achieving HbA1c <7.0% or <6.5%, weight loss ≥5% and a post‐hoc composite endpoint (HbA1c reduction of ≥1%‐point and weight loss ≥5%). These endpoints were reported for patients on semaglutide at EOS [effectiveness analysis set (EAS)]. Safety data were reported in the full analysis set. Results: Of 579 patients who initiated semaglutide (full analysis set), 491 completed the study on treatment (EAS). Mean baseline HbA1c was 8.0%, and 20.7% (120 of 579) of patients had HbA1c <7.0%. Mean semaglutide dose at EOS was 0.66 ± 0.28 mg. In the EAS, mean HbA1c and body weight decreased by 1.1%‐point (95% confidence interval 1.20, 1.05; P < .0001) and 4.2 kg (95% confidence interval 4.63, 3.67; P < .0001), respectively. At EOS, 61.7% and 40.8% of patients achieved HbA1c <7.0% and <6.5%, respectively, 40.5% achieved weight loss ≥5% and 25.3% achieved the post‐hoc composite endpoint. Patient‐reported outcomes improved from baseline to EOS. No new safety concerns were identified. Conclusions: In routine clinical practice in Italy, patients with T2D treated with once‐weekly semaglutide for 30 weeks achieved clinically significant improvements in HbA1c, body weight and other outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.15020

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 18

  1. International Diabetes Federation.IDF Diabetes Atlas 10th Edition. Accessed November 15 2022.https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
  2. 10.1016/j.numecd.2022.01.026 · DOI
  3. 10.2337/dc23-S004 · DOI · Paper page
  4. 10.1007/s00592-022-01857-4 · DOI
  5. 10.1016/j.phrs.2020.105052 · DOI
  6. 10.1016/S2213-8587(17)30085-2 · DOI · Paper page
  7. 10.1016/S2213-8587(18)30024-X · DOI · Paper page
  8. 10.1007/s12325-018-0805-y · DOI · Paper page
  9. 10.1001/jama.2013.281053 · DOI · Paper page
  10. 10.1002/pds.1471 · DOI · Paper page
  11. 10.1111/dom.14468 · DOI · Paper page
  12. 10.3390/jcm11174938 · DOI
  13. 10.1007/s13300-022-01218-y · DOI · Paper page
  14. 10.3389/fendo.2022.892702 · DOI
  15. 10.36171/jamd22.25.2.5 · DOI
  16. 10.1007/s13300-020-00984-x · DOI · Paper page
  17. 10.1210/10.1210/er.2006-0038 · DOI · Paper page
  18. 10.1111/dom.14765 · DOI · Paper page

Cited by

See all 32

Metadata

Authors
Napoli, R., Berra, C., Catarig, A., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2023-03-12
Volume
25
Issue
6
Pages
1658-1667
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W4320855956
Cited by
32
References
16
FWCI
5.29
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study. https://app.cochat.ai/papers/10.1111/dom.15020
The paper
Napoli, R., Berra, C., Catarig, A., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F. (2023). Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.